Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StayDry withdrawal strategy study in pediatric urinary incontinence
2023-510280-35-00Phase 4Completed
- Sponsor
- Central Denmark Region
- Start
- May 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of solifenacin and mirabegron in urinary incontinence (UI), sponsored by Central Denmark Region. Primary endpoint: Recurrence of incontinence after withdrawal. Started May 2024; status: completed.
02
Drugs
solifenacinmirabegron
03
Conditions
urinary incontinence (UI)
Beyond the preview
Go deeper on 2023-510280-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510280-35-00.